title: High rate of clinical recurrence in patients with Vogt-Koyanagi-Harada disease treated with early high-dose corticosteroids.
abstract: OBJECTIVE
  To analyse the rate of clinical recurrences in Brazilian patients with Vogt-Koyanagi-Harada (VKH) disease after early high-dose corticosteroid treatment.
  
  
  METHODS
  Retrospective study including patients treated with early high-dose corticosteroids (prednisone, 1-1.5 mg/kg/day, or 3-day 1 g methylprednisolone pulsetherapy) within 1 month from disease onset followed by slow taper (at least 6 months). Patients with a minimum 12-month follow-up were subdivided based on the presence of disease recurrence or persistence after 6 months from initial presentation into: acute-resolved (AR, no recurrences), chronic-recurrent (CR), and chronic-recurrent with subretinal fibrosis (SRF). Recurrences were defined as the presence of clinical and/or fluorescein angiography findings.
  
  
  RESULTS
  Twenty-nine patients (58 eyes) with a median follow-up of 65 months were included. Six (21 %), 11 (38 %) and 12 (41 %) patients were allocated to AR, CR, and SRF groups respectively. Though having received treatment within 1 month of onset, median time to initial treatment differed among groups (11, 15, and 25 days, in AR, CR, and SRF groups respectively). Intensity of immunosuppression, cataract development, and longer time to achieve logMAR visual acuity ≤0.8 differed significantly among the groups, being more severe in SRF group. HLA-DRB1*0405 allele followed the same trend, though not reaching significance (0.5 in AR group, 0.6 in CR, and 0.8 in SRF).
  
  
  CONCLUSIONS
  VKH disease in Brazilian patients evolved to chronic-recurrent disease in 79 % of cases; 38 % developed subretinal fibrosis, in spite of similar initial treatment regimens. Time to initiate treatment influenced outcomes.
authors.affiliation: Department of Ophthalmology, Faculdade de Medicina, Universidade São Paulo, Rua Diana 863 apto 91J, São Paulo, SP, 05.019-000, Brazil.
authors.forename: Viviane M
authors.initials: VM
authors.lastname: Sakata
authors.forename: Felipe T
authors.initials: FT
authors.lastname: da Silva
authors.forename: Carlos E
authors.initials: CE
authors.lastname: Hirata
authors.forename: Maria Lucia C
authors.initials: ML
authors.lastname: Marin
authors.forename: Helcio
authors.initials: H
authors.lastname: Rodrigues
authors.forename: Jorge
authors.initials: J
authors.lastname: Kalil
authors.forename: Rogerio A
authors.initials: RA
authors.lastname: Costa
authors.forename: Joyce H
authors.initials: JH
authors.lastname: Yamamoto
mesh_terms: D000293:Adolescent; D000328:Adult; D001938:Brazil / Q000453:epidemiology; D002648:Child; D002908:Chronic Disease; D005260:Female; D005355:Fibrosis; D005451:Fluorescein Angiography; D005938:Glucocorticoids / Q000008:administration & dosage*; D059811:HLA-DRB1 Chains / Q000235:genetics; D006801:Humans; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage*; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D011241:Prednisone / Q000008:administration & dosage*; D011379:Prognosis; D020551:Pulse Therapy, Drug; D012008:Recurrence; D012160:Retina / Q000473:pathology; D012189:Retrospective Studies; D014607:Uveomeningoencephalitic Syndrome / Q000175:diagnosis* / Q000188:drug therapy* / Q000453:epidemiology; D055815:Young Adult
chemical_list: D005938:Glucocorticoids; D059811:HLA-DRB1 Chains; C493960:HLA-DRB1*04:05 antigen; D011241:Prednisone; D008775:Methylprednisolone